SG10201811365RA - Slow-release conjugates of sn-38 - Google Patents
Slow-release conjugates of sn-38Info
- Publication number
- SG10201811365RA SG10201811365RA SG10201811365RA SG10201811365RA SG10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA
- Authority
- SG
- Singapore
- Prior art keywords
- slow
- conjugates
- release
- release conjugates
- glucuronate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361887111P | 2013-10-04 | 2013-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201811365RA true SG10201811365RA (en) | 2019-02-27 |
Family
ID=51871275
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602258WA SG11201602258WA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
SG10201811365RA SG10201811365RA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602258WA SG11201602258WA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10016411B2 (ja) |
EP (1) | EP3052101B1 (ja) |
JP (2) | JP6473145B2 (ja) |
KR (1) | KR102320753B1 (ja) |
CN (1) | CN106061483B (ja) |
AU (2) | AU2014331591B2 (ja) |
BR (1) | BR112016007410B1 (ja) |
CA (1) | CA2925132C (ja) |
DK (1) | DK3052101T3 (ja) |
ES (1) | ES2759905T3 (ja) |
MX (1) | MX371201B (ja) |
SG (2) | SG11201602258WA (ja) |
TW (1) | TWI716342B (ja) |
WO (1) | WO2015051307A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX371201B (es) * | 2013-10-04 | 2020-01-22 | Prolynx Llc | Conjugados de liberación lenta de sn-38. |
CN107375288B (zh) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
EP3613792B1 (en) | 2017-04-21 | 2021-02-24 | Bright Gene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
AU2019206623A1 (en) * | 2018-01-12 | 2020-07-16 | Prolynx Llc | Synergistic cancer treatment |
JP2022501341A (ja) * | 2018-09-17 | 2022-01-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | ポリマーベースの高分子プロドラッグ |
BR112021020023A2 (pt) * | 2019-04-05 | 2021-12-07 | Prolynx Llc | Ligantes de conjugação melhorados |
BR112022003649A2 (pt) * | 2019-08-28 | 2022-07-19 | Prolynx Llc | Inibidores conjugados de resposta ao dano no dna |
CA3193485A1 (en) | 2020-09-28 | 2022-03-31 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Peptidic conjugates of sn38 useful in the treatment of cancer |
US11976196B2 (en) * | 2021-04-14 | 2024-05-07 | Cambridge Crops, Inc. | Silk packaging applications |
AR128900A1 (es) | 2022-03-28 | 2024-06-26 | Sant Joan De Deu Hospital | Sistema de administración hidrosoluble peptídico de medicamentos contra el cáncer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
CA2491661A1 (en) * | 2002-07-12 | 2004-01-22 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
US7495099B2 (en) | 2002-10-31 | 2009-02-24 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
SI1675622T1 (sl) | 2003-09-17 | 2017-09-29 | Nektar Therapeutics | Večkraka polimerna predzdravila |
US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
RU2009114154A (ru) * | 2006-09-15 | 2010-10-20 | Энзон Фармасьютикалз, Инк. (Us) | Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры |
JP2012506380A (ja) * | 2008-10-21 | 2012-03-15 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 7−エチル−10−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療 |
US20100126866A1 (en) | 2008-11-18 | 2010-05-27 | Baxter Healthcare S.A. | Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample |
WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
JP5951496B2 (ja) * | 2009-11-18 | 2016-07-13 | ネクター セラピューティクス | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
US8703907B2 (en) * | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
JP2012000072A (ja) * | 2010-06-18 | 2012-01-05 | Japan Health Science Foundation | 新規な抗フィブリン抗体 |
AR082806A1 (es) * | 2010-08-30 | 2013-01-09 | Sun Pharma Advanced Res Co Ltd | Composicion farmaceutica estable |
JP5899241B2 (ja) * | 2010-12-21 | 2016-04-06 | ネクター セラピューティクス | ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート |
WO2013036857A1 (en) * | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
MX371201B (es) * | 2013-10-04 | 2020-01-22 | Prolynx Llc | Conjugados de liberación lenta de sn-38. |
-
2014
- 2014-10-03 MX MX2016004299A patent/MX371201B/es active IP Right Grant
- 2014-10-03 DK DK14796322.7T patent/DK3052101T3/da active
- 2014-10-03 CA CA2925132A patent/CA2925132C/en active Active
- 2014-10-03 KR KR1020167011936A patent/KR102320753B1/ko active IP Right Grant
- 2014-10-03 SG SG11201602258WA patent/SG11201602258WA/en unknown
- 2014-10-03 TW TW103134678A patent/TWI716342B/zh active
- 2014-10-03 EP EP14796322.7A patent/EP3052101B1/en active Active
- 2014-10-03 BR BR112016007410-6A patent/BR112016007410B1/pt active IP Right Grant
- 2014-10-03 JP JP2016520004A patent/JP6473145B2/ja active Active
- 2014-10-03 ES ES14796322T patent/ES2759905T3/es active Active
- 2014-10-03 AU AU2014331591A patent/AU2014331591B2/en active Active
- 2014-10-03 US US15/026,579 patent/US10016411B2/en active Active
- 2014-10-03 WO PCT/US2014/059146 patent/WO2015051307A1/en active Application Filing
- 2014-10-03 SG SG10201811365RA patent/SG10201811365RA/en unknown
- 2014-10-03 CN CN201480062543.4A patent/CN106061483B/zh active Active
-
2018
- 2018-06-14 US US16/009,078 patent/US10342792B2/en active Active
- 2018-11-01 AU AU2018256608A patent/AU2018256608A1/en not_active Abandoned
-
2019
- 2019-01-24 JP JP2019010029A patent/JP6842479B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
MX371201B (es) | 2020-01-22 |
AU2014331591B2 (en) | 2018-08-16 |
JP2016531895A (ja) | 2016-10-13 |
JP2019104739A (ja) | 2019-06-27 |
CN106061483B (zh) | 2021-01-08 |
CA2925132A1 (en) | 2015-04-09 |
US10342792B2 (en) | 2019-07-09 |
AU2014331591A1 (en) | 2016-05-19 |
US20160243106A1 (en) | 2016-08-25 |
EP3052101B1 (en) | 2019-11-20 |
EP3052101A1 (en) | 2016-08-10 |
BR112016007410A8 (pt) | 2020-02-27 |
BR112016007410B1 (pt) | 2022-07-19 |
MX2016004299A (es) | 2016-10-04 |
SG11201602258WA (en) | 2016-04-28 |
BR112016007410A2 (pt) | 2017-08-01 |
TW201601759A (zh) | 2016-01-16 |
DK3052101T3 (da) | 2019-12-16 |
CN106061483A (zh) | 2016-10-26 |
TWI716342B (zh) | 2021-01-21 |
US10016411B2 (en) | 2018-07-10 |
KR20160065203A (ko) | 2016-06-08 |
JP6842479B2 (ja) | 2021-03-17 |
ES2759905T3 (es) | 2020-05-12 |
JP6473145B2 (ja) | 2019-02-20 |
CA2925132C (en) | 2021-11-30 |
WO2015051307A1 (en) | 2015-04-09 |
KR102320753B1 (ko) | 2021-11-02 |
US20180289695A1 (en) | 2018-10-11 |
AU2018256608A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201811365RA (en) | Slow-release conjugates of sn-38 | |
IL245347A0 (en) | Continuous oral drug delivery | |
IL278183B (en) | Proton binding polymers for oral administration | |
MY170719A (en) | Antibody-drug conjugates | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
EP3082817A4 (en) | Compositions for drug administration | |
EP2968753A4 (en) | ANGULAR INTRODUCER FOR INFUSION OF MEDICINE | |
HK1214819A1 (zh) | 二環 -苯並二氮雜䓬和螺環取代的 -苯並二氮雜䓬 | |
EP3077006A4 (en) | Polymer-carbohydrate conjugates for drug delivery technology | |
IL263965A (en) | Cleavable drug polymer conjugates | |
EP3025527A4 (en) | Generating geofences | |
WO2014169007A3 (en) | Combination therapeutic nanoparticles | |
EP3161489A4 (en) | Markers and therapeutic indicators for glioblastoma multiforme (gbm) | |
MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
EP3082903A4 (en) | Wearable medication administration device | |
HK1213810A1 (zh) | 施用和相關的組合物、方法和系統 | |
IL269028A (en) | Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation | |
EP2952217A4 (en) | Medicinal cefoxitin vial, and dispensing apparatus and injection apparatus thereof | |
IN2013MU02015A (ja) | ||
IN2013MU01226A (ja) | ||
UA84204U (ru) | Способ иммунокоррекции больных ветряной оспой с наличием иммунодефицитных состояний | |
UA92247U (ru) | ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА | |
UA90140U (uk) | Пристрій для введення ультрадисперсних порошків в розпалав металу | |
IN2013MU03310A (ja) | ||
UA99990U (ru) | 2-амино-4-метил-9-(2,5-диметоксифенил)-7-оксо-3-циано-6,7,8,9-тетрагидропиридо[3',2':4,5]тиено[3,2-b]пиридин |